Blood-brain barrier-crossing antibodies

VHH nanobodies targeting human and non-human primate transferrin receptors enable efficient delivery of therapeutic and diagnostic agents across the blood-brain barrier, addressing the challenge of BBB permeability and improving treatment efficacy and safety.

JP2026519919APending Publication Date: 2026-06-19VLAAMS INTERUNIVERSITAIR INST VOOR BIOTECHNOLOGIE VZW +1
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
VLAAMS INTERUNIVERSITAIR INST VOOR BIOTECHNOLOGIE VZW
Filing Date
2024-04-02
Publication Date
2026-06-19

AI Technical Summary

Technical Problem

The blood-brain barrier (BBB) hinders the delivery of pharmaceutical compounds to the central nervous system, as most biologics cannot cross it effectively, leading to low brain target penetration and high treatment costs with potential side effects.

Method used

Development of antibodies, specifically VHH nanobodies, that bind to both human and non-human primate transferrin receptors (TfRs), enabling receptor-dependent endocytosis and transcytosis for efficient delivery of therapeutic and diagnostic agents across the BBB.

Benefits of technology

The VHH nanobodies facilitate the delivery of therapeutic and diagnostic agents into the brain after a single systemic administration, improving chemical stability, thermal stability, and reducing oligomerization and aggregation, thus enhancing the efficacy and safety of potential therapeutic conjugates.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2026519919000002
    Figure 2026519919000002
  • Figure 2026519919000003
    Figure 2026519919000003
  • Figure 2026519919000004
    Figure 2026519919000004
Patent Text Reader

Abstract

This invention relates to antibodies or antibody fragments that bind to human and non-human primate transferrin receptors. The antibodies described herein can be used as agents for delivering pharmaceutical compounds intracellularly or transcellularly during receptor-dependent endocytosis and / or transcytosis. Since transferrin receptors are also present in blood-brain barrier endothelial cells, one aspect of this invention provides means and methods for increasing the delivery of pharmaceutical compounds to the central nervous system.
Need to check novelty before this filing date? Find Prior Art